Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 12/20 | 0.45 |
| ▸ | MMP1 | P03956 | 7/20 | 0.45 |
| ▸ | MMP3 | P08254 | 6/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.45 |
| ▸ | ADAM9 | Q13443 | 5/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | AREG | P15514 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12992250 | 1.00 | CHEK1 (0.46) | CHEK1JAK2MMP9MMP1MMP3 | |
| SCHEMBL29177033 | 0.85 | CHEK1 (0.47) | CHEK1JAK2MMP9MMP1MMP3 | |
| SCHEMBL16879293 | 0.83 | NR1D1 (0.59) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL15704265 | 0.83 | CHEK1 (0.48) | CHEK1JAK2MMP9MMP1MMP3 | |
| SCHEMBL15704266 | 0.83 | CHEK1 (0.48) | CHEK1JAK2MMP9MMP1MMP3 | |
| SCHEMBL12878828 | 0.83 | CHEK1 (0.45) | CHEK1JAK2MMP9MMP1MMP3 | |
| SCHEMBL28611516 | 0.83 | CHEK1 (0.45) | CHEK1JAK2MMP9MMP1MMP3 | |
| SCHEMBL29655525 | 0.83 | CHEK1 (0.45) | CHEK1JAK2MMP9MMP1MMP3 | |
| SCHEMBL8278531 | 0.81 | NOTUM (0.48) | CHEK1JAK2MMP9MMP1MMP3 | |
| SCHEMBL32676972 | 0.81 | ACE (0.54) | CHEK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4276534-A1 | MASK BLANK, RESIST PATTERN FORMING PROCESS AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION | Shin-Etsu Chemical Co., Ltd. (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | CHEK1 4089/4885JAK2 1405/4885MMP9 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.